Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H26N2O4 |
| Molecular Weight | 370.4421 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]5(CC(=O)CC[C@@]35O)C2=C1O
InChI
InChIKey=RYIDHLJADOKWFM-MAODMQOUSA-N
InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
Samidorphan was developed as a sublingually bioavailable µ-opioid receptor antagonist. This drug participated in clinical trials for the treatment of Schizophrenia, Alcohol Dependence, and Binge Eating Disorder. The oral dose pharmacokinetics, safety, and tolerability of samidorphan were evaluated in phase II double blind, placebo-controlled, randomized studies in healthy adults. In addition, the combination of samidorphan (SAM) with buprenorphine (BUP) was studied in phase III clinical trial in patients with major depressive disorder (MDM). It was shown that the long-term treatment did not reveal any new safety findings and confirmed that the risk of abuse and dependence with BUP/SAM was low.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152293
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
100000164891
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
11667832
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
DTXSID401030402
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
CHEMBL426084
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
7W2581Z5L8
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
SUB179484
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
852626-89-2
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
9515
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
2559612
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
DB12543
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
XX-137
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
7W2581Z5L8
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY | |||
|
SAMIDORPHAN
Created by
admin on Sat Dec 16 01:45:57 UTC 2023 , Edited by admin on Sat Dec 16 01:45:57 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
